×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
04:11 pm
bmrn
CAMP4 Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
CAMP4 Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/20
11:12 am
bmrn
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]
Low
Report
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]
11/19
07:02 pm
bmrn
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
11/16
10:47 am
bmrn
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 [Yahoo! Finance]
Low
Report
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 [Yahoo! Finance]
11/16
10:45 am
bmrn
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Low
Report
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
11/15
08:04 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
Medium
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
11/7
09:50 am
bmrn
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) [Yahoo! Finance]
Low
Report
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) [Yahoo! Finance]
11/6
05:40 pm
bmrn
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market Evolution - Technavio [Yahoo! Finance]
Low
Report
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market Evolution - Technavio [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2024
04:03 pm
BMRN
biomarin pharmaceutical inc.
BEAT
Report
-4.6%
biomarin pharmaceutical inc.
8/5/2024
04:03 pm
BMRN
biomarin pharmaceutical inc.
BEAT
Report
8.0%
biomarin pharmaceutical inc.
4/24/2024
04:03 pm
BMRN
biomarin pharmaceutical inc.
BEAT
Report
-9.9%
biomarin pharmaceutical inc.
2/22/2024
04:03 pm
BMRN
biomarin pharmaceutical inc.
BEAT
Report
1.4%
biomarin pharmaceutical inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
02:45 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Nov 12 Filed by: Guyer Charles Greg
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Nov 12 Filed by: Guyer Charles Greg
11/12
02:27 pm
bmrn
Form 144 BIOMARIN PHARMACEUTICAL Filed by: Guyer Charles Greg
Low
Report
Form 144 BIOMARIN PHARMACEUTICAL Filed by: Guyer Charles Greg
10/31
03:01 pm
bmrn
Form 10-Q BIOMARIN PHARMACEUTICAL For: Sep 30
Low
Report
Form 10-Q BIOMARIN PHARMACEUTICAL For: Sep 30
10/29
04:04 pm
bmrn
Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 29
Medium
Report
Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 29
10/1
04:52 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Sep 30 Filed by: Friberg Gregory R
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Sep 30 Filed by: Friberg Gregory R
10/1
04:50 pm
bmrn
Form 3 BIOMARIN PHARMACEUTICAL For: Sep 30 Filed by: Friberg Gregory R
Low
Report
Form 3 BIOMARIN PHARMACEUTICAL For: Sep 30 Filed by: Friberg Gregory R
9/30
04:29 pm
bmrn
Form SC 13G BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
Low
Report
Form SC 13G BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
9/24
08:32 am
bmrn
Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 24
Low
Report
Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 24
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES
7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
TOP News Decliners
3/11
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES
-12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: